Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease

被引：0
|
作者：
Marcel N Menke
Carsten Framme
Mathias Nelle
Markus R Berger
Veit Sturm
Sebastian Wolf
机构：
[1] Bern University Hospital,Department of Ophthalmology, Inselspital
[2] and University of Bern,University Eye Hospital
[3] Medical School Hannover,Department of Neonatology, Inselspital
[4] Bern University Hospital,Department of Ophthalmology
[5] and University of Bern,Department of Ophthalmology
[6] Cantonal Hospital St. Gallen,undefined
[7] Cantonal Hospital Aarau,undefined
来源：
BMC Ophthalmology | / 15卷
关键词：
Retinopathy of prematurity; Ranibizumab; Bevacizumab; Plus disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
    Menke, Marcel N.
    Framme, Carsten
    Nelle, Mathias
    Berger, Markus R.
    Sturm, Veit
    Wolf, Sebastian
    [J]. BMC OPHTHALMOLOGY, 2015, 15
  • [2] Evaluation of monotherapy of intravitreal Bevacizumab in retinopathy of prematurity stage 3 plus
    Shirzadeh, S.
    [J]. ACTA OPHTHALMOLOGICA, 2016, 94
  • [3] Analysis of the Recurrence of Plus Disease after Intravitreal Ranibizumab as a Primary Monotherapy for Severe Retinopathy of Prematurity
    Arambulo, Odalis
    Dib, Gabriel
    Iturralde, Juan
    Brito, Miguel
    Fortes Filho, Joao B.
    [J]. OPHTHALMOLOGY RETINA, 2018, 2 (08): : 858 - 863
  • [4] Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis
    Fengjie Xia
    Jiao Lyu
    Jie Peng
    Peiquan Zhao
    [J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 2837 - 2846
  • [5] Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis
    Xia, Fengjie
    Lyu, Jiao
    Peng, Jie
    Zhao, Peiquan
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (09) : 2837 - 2846
  • [6] Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity
    Larranaga-Fragoso, Paula
    Peralta, Jesus
    Bravo-Ljubetic, Luciano
    Pastora, Natalia
    Abelairas-Gomez, Jose
    [J]. JOURNAL OF PEDIATRIC OPHTHALMOLOGY & STRABISMUS, 2016, 53 (06) : 375 - 382
  • [7] Refractive, Visual and Retinal Outcomes after Intravitreal Ranibizumab Monotherapy for Retinopathy of Prematurity
    Alhassan, Nora Hassan
    Abohaimed, Foziyah
    Albalawi, Maram
    Aldarwesh, Amal
    Aldibasi, Omar
    Hazzazi, Mohammed
    Fahmy, Rania Medhat
    [J]. OPEN OPHTHALMOLOGY JOURNAL, 2023, 17
  • [8] Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors
    Lyu, Jiao
    Zhang, Qi
    Chen, Chun-Li
    Xu, Yu
    Ji, Xun-Da
    Li, Jia-Kai
    Huang, Qiu-Jing
    Zhao, Pei-Quan
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (03) : 1719 - 1725
  • [9] Outcomes of treatment with intravitreal ranibizumab and laser photocoagulation for severe zone I and posterior zone II retinopathy of prematurity
    Ahlers, Carolyn Grace
    Valenzuela, Daniel A.
    De la Huerta, Irina
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [10] Recurrence of Retinopathy of Prematurity in Zone II Stage 3+after Ranibizumab Treatment: A Retrospective Study
    Hu, Qinrui
    Bai, Yujing
    Chen, Xiaoli
    Huang, Lvzhen
    Chen, Yi
    Li, Xiaoxin
    [J]. JOURNAL OF OPHTHALMOLOGY, 2017, 2017
12345